Nanodelivery of BA receptor modulators—such as the FXR agonist obeticholic acid (OCA) and the GPBAR1 antagonist 5β-cholanic acid (5β-CA)—enhanced NK, NKT, and CD8+ T cell infiltration and triggered potent anti-tumor responses in liver cancer models (152). Here, CD8A is linked to neoplasm.